Vivo Capital, LLC - Q3 2018 holdings

$992 Million is the total value of Vivo Capital, LLC's 44 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .

 Value Shares↓ Weighting
CRNX NewCrinetics Pharmaceuticals Inc$108,646,0003,792,169
+100.0%
10.95%
SVA NewSinovac Biotech Ltd$44,958,0005,900,000
+100.0%
4.53%
XENE NewXenon Pharmaceuticals Inc$18,552,0001,405,476
+100.0%
1.87%
ACER NewAcer Therapeutics Inc$17,442,000565,579
+100.0%
1.76%
ARVN NewArvinas Holding Co LLC$5,061,000300,000
+100.0%
0.51%
GTXI NewGTX Inc$165,000105,043
+100.0%
0.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ACLARIS THERAPEUTICS INC29Q3 202333.5%
CODEXIS INC29Q3 20238.0%
ASCENDIS PHARMA A/S25Q3 202224.0%
KALVISTA PHARMACEUTICALS INC25Q3 20233.9%
Verona Pharma PLC ADR24Q3 20237.6%
AMYRIS INC23Q3 20238.8%
EIGER BIOPHARMACEUTICALS INC23Q1 20228.7%
Zai Lab Ltd ADR22Q3 20231.8%
Arrowhead Pharmaceuticals Inc21Q3 20236.9%
HOMOLOGY MEDICINES INC21Q3 20233.7%

View Vivo Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Vivo Capital, LLC Q3 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SINOVAC BIOTECH LTDSold outAugust 27, 201800.0%

View Vivo Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-04-22
13F-HR2024-02-07
13F-HR2023-11-08
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-13
13F-HR2022-02-11

View Vivo Capital, LLC's complete filings history.

Compare quarters

Export Vivo Capital, LLC's holdings